Valuation check: BFRIW's profit margin is -13.78%, below the Healthcare sector average of 13.76%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Biofrontera- Warrants (27/10/2026) posts a profit margin of -13.78% as of June 2026. That compares with -42.35% in the prior-year period — up 67.4% year over year. That is below the Healthcare sector average of 13.76%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Biofrontera- Warrants (27/10/2026)'s profit margin was -42.35%. The latest reading is -13.78% — a 67.4% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a profit margin near 13.76% is typical. Biofrontera- Warrants (27/10/2026)'s -13.78% is lower that level. That is roughly 200.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Biofrontera- Warrants (27/10/2026)'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -13.78% as of June 2026; use YoY and peer views to separate noise from signal.
Context for BFRIW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.76%), and (3) consistency with growth and profitability. This page covers the first two; Biofrontera- Warrants (27/10/2026)'s other metric pages and overview cover the third.